GARDASIL®9 Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21February 26, 2015 3:33 pm | News | Comments
Merck has announced that the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to include GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in the recommendations for use of HPV vaccines.
Merck has granted a free license allowing one of its HIV medicines to be made and sold...
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck announced they...
Zachary Zwerko pleaded guilty in Manhattan federal court to conspiring to commit securities...
Under the terms of the agreement, NewLink Genetics will receive a payment of $20 million in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
Insomnia drug sales will fall rapidly from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023, driven by the launch of two products, Merck & Co.’s Belsomra and Eisai’s E-2006, and an increase in the prevalent cases of insomnia, says research and consulting firm GlobalData.
Merck has announced that the company and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of Erbitux® (cetuximab) to Merck in Japan as of May 1, 2015
Merck's fourth-quarter profit skyrocketed to $7.32 billion, skewed by an $11.2 billion gain from selling its consumer health business to Germany's Bayer AG.
Merck has announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States.
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO® for the treatment of acute bacterial skin and skin structure infections in adults.
Moderna Therapeutics has announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).
Merck is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer.
Merck and Eli Lilly announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.
Merck today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth.
After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines — one made by GlaxoSmithKline and the other licensed by Merck and NewLink — have "an acceptable safety profile."
EnWave Corporation has signed a non-exclusive Research and Development License Agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary to enable testing and advancement of the Company's Radiant Energy Vacuum ("REV™") dehydration technology in the pharmaceutical industry.
The Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services has awarded NewLink Genetics' subsidiary, BioProtection Systems, as the prime contractor in a $30M contract to support the manufacturing and development activities of its investigational Ebola vaccine candidate.
Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
The FDA has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil, Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.
Merck will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer.
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the company's patents protecting its top-selling antibiotic just hours after the deal was announced this week.
Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.
Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.
Merck and NewLink Genetics Corporation have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.
A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
Merck announced today that it has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.
Scientists have discovered some rare gene mutations that give people naturally lower cholesterol levels and cut their risk of heart disease in half. The news is of great interest because a drug that mimics these mutations has long been sold without evidence that it cuts the chance of heart disease, even though it lowers cholesterol.
Merck's third-quarter net income fell mostly because of large costs tied to acquisitions and divestitures. But the company's adjusted earnings topped Wall Street's view, and it narrowed its full-year adjusted earnings forecast on Monday.
A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits.
- Page 1